Pharmaceuticals (Mar 2024)

Identification and Development of BRD9 Chemical Probes

  • Ester Colarusso,
  • Maria Giovanna Chini,
  • Giuseppe Bifulco,
  • Gianluigi Lauro,
  • Assunta Giordano

DOI
https://doi.org/10.3390/ph17030392
Journal volume & issue
Vol. 17, no. 3
p. 392

Abstract

Read online

The development of BRD9 inhibitors involves the design and synthesis of molecules that can specifically bind the BRD9 protein, interfering with the function of the chromatin-remodeling complex ncBAF, with the main advantage of modulating gene expression and controlling cellular processes. Here, we summarize the work conducted over the past 10 years to find new BRD9 binders, with an emphasis on their structure–activity relationships, efficacies, and selectivities in preliminary studies. BRD9 is expressed in a variety of cancer forms, hence, its inhibition holds particular significance in cancer research. However, it is crucial to note that the expanding research in the field, particularly in the development of new degraders, may uncover new therapeutic potentials.

Keywords